Doing bespoke work since 2002....., Custom Products Group

Patrick Hansen

Doing bespoke work since 2002.....

Custom Products Group

Custom Products was started 14 years ago at Lehman Brothers by current co-founder Patrick Hansen, CFA. After 3 years at Lehman, Patrick moved the team to Macquarie Securities where Simon Rigney (co-founder) joined. 3 years ago we took Custom Products independent. 

Our core strength can be summed up three words. 1- Customization - we have very little off the shelf products and most work is done on a one on one bespoke basis. 2- Speed - We pride ourselves in our ability to get requests back to the client very quickly. 3- Confidentiality - We do not redistribute. There is no grace period where we wait a week and then mass blast. Any request stops with that client.

Thematic (Sector/Industry)

<p>With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half. Names that could potentially beat full-year estimates. We basically screened for names that have already achieved greater than 60% of full-year consensus OP estimates and have also increased full-year Company OP guidance in the last month. </p><h2>Screen Criteria</h2><ol>
<li>Mkt-cap above ¥50bn</li>
<li>Fiscal year ending on March 31</li>
<li>Greater than 60% of full-year OP consensus is…</li>
</ol>

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half. Names that could potentially beat full-year estimates. We basically screened for names that have already achieved greater than 60% of full-year consensus OP estimates and have also increased full-year Company OP guidance in the last month. Screen Criteria
Mkt-cap above ¥50bn
Fiscal year ending on March 31
Greater than 60% of full-year OP consensus is…


Names Potentially Well Positioned to Beat Year-End Estimates

Making sense of the Global Market, Euromonitor International Ltd.

Yu Mitsuhashi

Making sense of the Global Market

Euromonitor International Ltd.

We are a global market research company focused on industries, countries, economies and consumers worldwide. Our cross-country comparable research helps your organisation identify opportunities and develop growth strategies in countries and regions across the globe. With offices around the world, 1,200 analysts in 100 countries and market research on every key trend and driver, we give you powerful access to the real story behind consumer change.

<ul><li><strong>Industry’s growth facilitated by healthcare spending as Japan’s society ages</strong><ul><li>The revenue of Japanese pharmaceutical producers continued to grow in 2016, primarily due to rising sales to domestic healthcare service providers.</li></ul></li><li><strong>Positive outlook clouded by government policies aimed at containing health costs</strong><ul><li>The industry’s value growth potential will be clouded by rising pricing pressures both from government policies, and rising consumption share of generic drugs.</li></ul></li></ul>

Industry’s growth facilitated by healthcare spending as Japan’s society agesThe revenue of Japanese pharmaceutical producers continued to grow in 2016, primarily due to rising sales to domestic healthcare service providers.Positive outlook clouded by government policies aimed at containing health costsThe industry’s value growth potential will be clouded by rising pricing pressures both from government policies, and rising consumption share of generic drugs.

Industrial Capsule: Pharmaceuticals in Japan

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analysed the earning revision of component stocks of MS-Japan in the past month.</li>
<li>We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.</li>
<li>We highlighted EPS revision on Mitsubishi UFJ Financial, Toyota Motor, Ana, Toyota Industries, Nissan Motor, Mizuho Financial, Honda Motor.</li>
</ul>


We analysed the earning revision of component stocks of MS-Japan in the past month.
We tabulated stocks with the top impact on index's EPS, stocks' EPS revision, and revenue revision.
We highlighted EPS revision on Mitsubishi UFJ Financial, Toyota Motor, Ana, Toyota Industries, Nissan Motor, Mizuho Financial, Honda Motor.


MS-Japan Index Earning Revision (Apr): Mitsubishi UFJ Financial, Toyota Motor, Ana

Analyst

Alasdair Moody

Exposing Creative Accounting

Bucephalus Research Partnership

Bucephalus Research Partnership Limited. Exposing Creative Accounting.

At the Bucephalus Research Partnership (BRP) we analyse financial statements using our accountant's practical experience and our own quantitative algorithms for corporate governance, accounting risk and peer performance.

Our thematic research refines our unique algorithms while our single stock research focuses on examples where we discover a significant gap between published accounts and business reality.

​Bucephalus Research Partnership:
- Is an independent fee-based research service
- Does not take proprietary positions, long or short
- Does not solicit business or fees from the corporates we review

<p>We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…</p>

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created statistics for each region based on aggregate data and for a typical company. In this trend report, we summarise the data and highlight the outliers. Assuming clients will have their own macro industry views, we used valuations and our Governance, Accounting risk and Peer performance (GAP) scores, (which help quantify the risk of creative accounting) to…

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/astellas-pharma-inc" target="_blank" data-smartkarma-citation="entities:6091:1" rel="noopener">Astellas Pharma (4503 JP)</a> reported 12% YoY revenue growth in FY26. Core operating profit increased to ¥555.7B, up 42% YoY driven by cost optimization through sustainable margin transformation program.</li>
<li>Strategic brands (Padcev, Izervay, Veozah, Vyloy, Xospata), which recorded underlying growth of 43% YoY and contributed 22% of revenue, drove overall revenue growth. Xtandi attains peak sales.</li>
<li>Astellas unveiled FY27 guidance where they expect FY27 revenue to be ¥2,220B (up 3.8% YoY), core operating profit of ¥620B (up 11.6% YoY) and core profit of ¥460B (+8.4% YoY).</li>
</ul>



Astellas Pharma (4503 JP) reported 12% YoY revenue growth in FY26. Core operating profit increased to ¥555.7B, up 42% YoY driven by cost optimization through sustainable margin transformation program.
Strategic brands (Padcev, Izervay, Veozah, Vyloy, Xospata), which recorded underlying growth of 43% YoY and contributed 22% of revenue, drove overall revenue growth. Xtandi attains peak sales.
Astellas unveiled FY27 guidance where they expect FY27 revenue to be ¥2,220B (up 3.8% YoY), core operating profit of ¥620B (up 11.6% YoY) and core profit of ¥460B (+8.4% YoY).


Astellas Pharma (4503 JP): Strategic Brands Shine in FY26 as Xtandi Peaks, FY27 Guidance Revealed

Japan

Takeda Pharmaceutical Co Ltd focuses on the Research & Development, Manufacturing, Sales and Marketing and Import/Export of Pharmaceutical Drugs. The Company focuses on the following core therapeutic areas: Cardiovascular & Metabolic, Oncology, Central Nervous System, Respiratory & Immunology, General Medicine (Gastrointestinal & Genitourinary) and Vaccine.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Takeda Pharmaceutical (4502 JP)

Names Potentially Well Positioned to Beat Year-End Estimates

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half....

Custom Products Group

Industrial Capsule: Pharmaceuticals in Japan

Industry’s growth facilitated by healthcare spending as Japan’s society agesThe revenue of Japanese pharmaceutical producers continued to grow in...

Euromonitor International Ltd.

MS-Japan Index Earning Revision (Apr): Mitsubishi UFJ Financial, Toyota Motor, Ana

We analyzed MS-Japan's consensus for Apr 2026 and highlighted changes of EPS in Mitsubishi UFJ Financial, Toyota Motor, Ana, Toyota Industries,...

Ke Yan, CFA, FRM

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

Bucephalus Research Partnership

Astellas Pharma (4503 JP): Strategic Brands Shine in FY26 as Xtandi Peaks, FY27 Guidance Revealed

Astellas Pharma sees strong revenue and profit growth in FY26, driven by strategic brands and cost optimization. This momentum is expected to...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Names Potentially Well Positioned to Beat Year-End Estimates

With a good portion of Japanese companies having already announced 1H results, we looked at the names that are well positioned for the second half....

Custom Products Group

Industrial Capsule: Pharmaceuticals in Japan

Industry’s growth facilitated by healthcare spending as Japan’s society agesThe revenue of Japanese pharmaceutical producers continued to grow in...

Euromonitor International Ltd.

MS-Japan Index Earning Revision (Apr): Mitsubishi UFJ Financial, Toyota Motor, Ana

We analyzed MS-Japan's consensus for Apr 2026 and highlighted changes of EPS in Mitsubishi UFJ Financial, Toyota Motor, Ana, Toyota Industries,...

Ke Yan, CFA, FRM

Global Pharmaceuticals: Valuations, Assets and Leverage Up - Margins Down

We examined ten years of accounting and valuation data for the pharmaceutical companies around the world with sales of US$100m+ and created...

Bucephalus Research Partnership

Astellas Pharma (4503 JP): Strategic Brands Shine in FY26 as Xtandi Peaks, FY27 Guidance Revealed

​Astellas Pharma sees strong revenue and profit growth in FY26, driven by strategic brands and cost optimization. This momentum is expected to...

Tina Banerjee

Astellas Pharma sees strong revenue and profit growth in FY26, driven by strategic brands and cost optimization. This momentum is expected to...